Skip to main content

Elbit Medical Technologies Ltd (EMTC-M.TA)

TLV Healthcare Medical - DevicesView data quality →
46.4Fair

ValueMarkers Composite Index

Top 17%#37,313 of 44,707
Undervalued

411% below intrinsic value ($4)

UndervaluedFair ValueOvervalued
Piotroski
3/9
Weak
Beneish
-
Altman
55.64
Safe
DCF Value
$4
Overvalued
ROIC
-2.5%
Low
P/E
82.0
Growth
Updated: ·Source: Data sourced from SEC filings and institutional providers. Not financial advice.·Report data issue

Elbit Medical Technologies Ltd (EMTC-M.TA) — VMCI valuation read

EMTC-M.TA screens at VMCI 46/100, a 4-point gap below the Healthcare sector median (50). For a mid-cap Elbit Medical Technologies Ltd share, that placement says the multi-pillar composite is richer or lower quality than the typical peer on a like-for-like basis.

EMTC-M.TA has logged no Form 4 insider activity over the trailing 30 days. The tape reads neither bullish nor bearish on insider conviction. The next signal sits with the 10-Q schedule and the analyst calendar.

**Investor frame.** Value: EMTC-M.TA trades at 24.0x earnings, 33% above the Healthcare median of 18.0x, while EV/EBITDA prints 9.0x against 12.0x for the Healthcare group. Quality: ROIC of 16.0% sits 6.0pp above the Healthcare median (10.0%), the cleanest like-for-like comparison on capital efficiency. Risk: net debt to EBITDA of -2.0x leaves covenant headroom, which sets the rate-cycle exposure for Elbit Medical Technologies Ltd.

EMTC-M.TA fell 1.0% over the trailing 7 days, with a -12.8% read on a 30-day basis.

Top peers ranked by VM Score. Compare valuation, quality, and risk metrics across the sector.

Browse More

Key metrics explained

Definitions, formulas, and how ValueMarkers calculates each indicator used in EMTC-M.TA’s VM Score.

Explore More

Compare Competitors

Weekly Stock Analysis - Free

5 undervalued stocks, fully modeled. Every Monday. No spam.

Cookie Preferences

We use cookies to analyze site usage and improve your experience. You can accept all, reject all, or customize your preferences.